Dermatology Services

VIP Research Study

A multicenter, randomized, double blind placebo controlled trial assessing the effect of adalimumab (Humira), when compared to NB-UVB phototherapy or placebo injection. The study will compare the effects of each on systemic inflammation and cardiovascular disease risk factors in subjects diagnosed with moderate to severe psoriasis.

Inclusion Criteria:

  • Must be 18 years of age or older
  • Have had a diagnosis of psoriasis for at least 6 months
  • Moderate to severe plaque type psoriasis with ≥10% body surface area

Study-related visits, medications, and tests will be provided to you at no cost if you qualify. You will be compensated for time and travel.

Contact:  Dr. Michael Caglia, 801-213-2629